That would be nice every investors dream 10x the market cap after a TH.
We know ADC is a complex biologic drug and it is highly immune to biosimilar competition. This is why ADC will command meaningful financials in revenues/TO due to its complexity.
Hence Pfizer paid 43B to acquire Seagen and IMO it is cheap.
Here hoping for a big pharma collaboration to rerate our undervalued sp.
